Iovance Biotherapeutics Inc (IOVA) 뉴스

SG Americas Securities LLC Buys Shares of 69,625 Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)

You forgot to mention that after the publication of the paper on Nature Communications those naysayers from medical field stopped publishing attacking pieces. Do you know why? Let me tell you why. Those people know very well that DCVax-L indeed can trigger intense and sustainable t-cell infiltration into tumor sites which matters the most in immunotherapy. They should be amazed that UCLA team can use GSVA score of a certain gene set after the vaccination to predict OS, which has never been achieved by any one else. See the following figure? The percentage of CD4 t-cells activated by DC vaccine which is essential to trigger immune memory outnumbers that of CD8 t-cells. CD14 monocytes which will differentiate into tumor-associated macrophages once seeping into tumor tissue is also significant, which clearly shows the tumor-associated macrophage immunosuppression that can be dealt with CSF1R inhibitor.

See those targets (highly overexpressed mutated genes) Genentech chose for their precision medicines for different types of cancers. If these targets happen to exist in three types of brain tumors, DCVax-L + Poly-iclc can fix the mutated genes.

This company has the biggest breakthrough in medicine ever. Once investors realize the true value of this company, the management will become one of the richest in the country. They have no interest in the small drop in a bucket. How's your prediciton on NVCR?

https://www.nature.com/articles/s41467-024-48073-y

NWBO's management is both morally and ethically corrupt. After many years of looking at this company, I have concluded the purpose of it is to transfer wealth from the public company into the pockets of private entities. They have been very successful at that!

The DCVax-L trial was negative [1-3] and not a single patient responded to DCVax-Direct [4].

When they went OTC were required to disclose "Third Party Advisors" providing "Promotion of the company" (paid pumpers) [5]. They do have a long history of paying third parties [6].

Refs:
1 https://academic.oup.com/neuro-oncology/article/25/4/631/6958519
2 https://www.sciencedirect.com/science/article/pii/S0035378723009190
3 https://www.practiceupdate.com/content/2022-top-story-in-oncology-dcvax-in-patients-with-newly-diagnosed-and-recurrent-glioblastoma/143631
4 https://aacrjournals.org/clincancerres/article/24/16/3845/277824/Cytokines-Produced-by-Dendritic-Cells-Administered
5 https://www.otcmarkets.com/stock/NWBO/disclosure
6 https://www.nasdaq.com/articles/behind-promotion-northwest-bio-2014-07-07

Thanks for the reply.

Had a longer response but iHub timed out the post. Short version:

1) The finances are critical. NWBO has cash runway of less than 1 quarter.
2) UK approval may provide milestones but this was licensed out so they will only get royalties and only after approval and reimbursement agreement.
3) US trial is P1 so it is years off.
4) Licensing deal pretty much takes any BO off the table.

I have learned that both the science AND the finances are critical in biotech. Many companies "survive" but generally the SP doesn't do well. Just my approach... as Badger says, its your money and your DD. Hope you do well, but not a company I would invest in.

The UK approval is pending. The science is truly amazing. Here is the figure from one patient in the combination of trial with Merck as one of the collaborators and the technology adopted in the trial was licensed from NWBO. The blue dots are cancer cells. Can you see the blue dots were significantly reduced after the second shot of the vaccine? The green dots are tumor-associated macrophages which suppress anti-tumor immune response. Those green dots can be depleted by an inhibitor called CSF1R inhibitor.

BTW, have you seen a company that can survive on OTC for nine years and be able to file for RA approval for the revolutionary technology? I assume you know Provenge developed by the Noble Prize winner Ralph Steinman. Do you know how many antigen his technology can make dendritic cell present to immune system? Only one tumor-specific antigen related to prostate cancer. Guess how many tumor antigens NWBO can make dendritic cells present to immune system. Hundreds of them. That's why for the most difficult cancer--glioblastoma, the trial has amazing data.

It is worth taking a closer look.


https://clinicaltrials.gov/study/NCT04201873

Regarding $NWBO, the finances are not good here and there are no near term catalysts that I can see.

Thanks.

Wow, 140k shares! That's a lot.
Take a look at $NWBO and use the rest capital of 60k to load $NWBO as a way to hedge your current investment.

I have been thinking about the Piper downgrade this weekend, trying to see how much merit there is to the assessment. Most people are dismissing the report, but given that this analyst was the only one who called Q2 correctly, I am wary to do so. The original analysis stated that ramp-up was slow because "The slow uptake is attributed to extended waits for manufacturing slots, which delay infusion times and may restrict patient eligibility." (link: https://www.investing.com/news/company-news/piper-sandler-sees-manufacturing-delays-impacting-iovance-stock-potential-93CH-3540561). This was also confirmed by U of Kansas docs as well as Boston General. The Piper projected 24 infusions which was very close to the 25 actual. However, I think the issues were more than simply slot availability (which I think has been fixed with additional hiring ). I think the issues also included:
1) initial (bolus) patient health with high drop rate early on - note 100+ patients "enrolled" at Q2 ER but only 55 infused at Q3 ER. Now resolved via patient selection
2) Extended initial cycle-time of +/-90 days. to +/-75 days at Q3 and reduced to +/-63 days.
3) At JPM, GS reported Fred saying "management had previously suggested that out-of-spec product was occurring primarily due to poor tumor resection quality, arising in part due to the large number of surgeons resecting samples and where the level of training had been variable. Accordingly, efforts to retrain surgeons on appropriate harvesting techniques focusing on quality and size have been implemented. Management noting that on average, outcomes improve after 2-3 patients but additional efforts are underway, particularly with new ATCs ... to ensure correct tumor resections are occurring with the first patient". (confirmed by U of Kansas docs and also supported by the enrolled to infused number reported in Q2/Q3.

So, the current Piper theory is that, based on the 6 ATCs they surveyed, they have reached a "steady state" of patients. Here is my take on that thesis:
1) I assume that these are the same 6 ATCs that responded to the first survey. As such, they would have been part of the initial 30 ATCs, which are much more likely to be at "steady state" than any subsequently onboarded ATC. Therefore, extrapolation to other ATCs would be inappropriate.
2) IOVA hired most of the regional marketing staff in the last 3 months so community out-reach has really just started.
3) OOS rates should drop (based on above) so even at steady state of patient beds, infusion rates should increase.
4) IOVA has increased staff by 50+ in the 2 months from Nov 7th ER to Jan 13th JPM, so unless these are all marketing/RoW rollout hires, seems like there is still manufacturing growth.
5) Looking at the balance sheet, starting in Q2 2023 (after Proleukin purchase), IOVA started reporting inventory numbers. This was all under WIP and Finished Goods and this was steady at about $10M total until Q1 2024 and has increased $2M/quarter since then. From this, I assume the initial $10M was for planned stocking (very small sales until Q2 2024) and the $2M quarterly increase was being driven by Amtagvi and Proleukin usage. The bigger thing is that raw materials jumped from $0 to $5.6M in Q1 to $13M in Q2 to $23.9M in Q3. This obviously was all driven by Amtagvi manufacturing and the only reason for that build up would be for increased manufacturing.

Bottom line, while Piper got the Q2 call correct, I think they are missing the boat with this call.

They have less than 1 quarter cash runway... always monitor the cash position in biotechs in relationship to any catalyst. Unless there is a clear path to profitability, you will be diluted endlessly... I have learned those companies are trades only.

It seems the sector is crazy lately. Here is another one that is crashing. RNAZ!

https://ih.advfn.com/stock-market/NASDAQ/transcode-therapeutics-RNAZ/stock-news/95244508/transcode-therapeutics-announces-first-patient-dos

Well said Hicham & Badger 🫡 very much agreed

Hicham, you're in good company. I've also increased my position, reduced my average cost, and I'm willing to add more shares in the coming months as my funds become available. I see more reasons now to be long IOVA than I did when the share price was $18. I'm also far more willing to wait for the multitudes of good news expected this year which most certainly should move the share price higher.

The sector has been a bear, but the low multiples that the biotechs are currently trading at should start returning to more realistic levels over the coming months and years. Lots of bargains out there right now including IOVA (or so I believe), but making good choices on what to buy and hold going forward is still the challenge. All of our due diligence on Iovance leading to our share purchases will likely result in very good returns.

Here's a little something I shared on another site: "These guys did okay. Catch Charlie's comment at 1:52:"



Good luck with your investing in 2025.

Painful but nothing new...

I have averaged down my portfolio to 6.6$ down from 9.8 and I have now 140k shares and i am ready to increase it to 200k if the SP continues on  dropping.  By now Iova is my only stock market investment so we can say all In...

I am ready financially to accept a SP drop to 3 because I know sooner or later we will be >20.

Just need to be patient...

As long as the small cohort we saw from LUN-202 scales there’s no issue. And every reason to think things will actually improve because of 2L patient requirement (2L-4L in COM-202) and also increased partial responses over time. I think more like ORR ~30% and mDOR >9 months. We’ll see by September during WCLC 😄

FUD or confusion? I'm seeing some comments being posted about Lung data with the usual what if comments on multiple message boards. Here's my view FWIW (and you're paying nothing for it, so that should establish its value).

TIL therapy works. That much you should know before spending your investment dollars on IOVA. 40 years of research has already proven that case. Where the challenge lies is in the commercialization of TIL therapy and creating a system that can succeed for both the patient and the profitability of the company - Iovance.

I'm investing in the ability of Iovance to succeed with its manufacturing capability and being organized in such a way as to meet the increasing demands of qualified patients while still turning a profit. For my purposes, TIL is already a given and will be approved for multiple cancers.

There were several bumps at the start last February and for several months due to logistics of managing multiple ATCs, docs, hospitals, surgical suites, and so on. Insurance was a minor concern, but that is also now almost fully resolved.

At the start, Amtagvi manufacturing capability at the iCTC wasn't fully ironed out. With lots of new hires, some initial staffing shortages, the usual when starting up what has never been done before, it was logical to assume some glitches. It's easy to criticize the launch, but you don't know what you don't know. Iovance did learn quickly and made all necessary corrections and adjustments.

There are now several reports and comments by the docs themselves that the process to treat patients with Amtagvi has been successfully organized and the operation from beginning to end is much smoother.

Do your due diligence, understand the facts of TIL therapy, the trial process, and what Iovance is doing to become the first and only successful TIL therapy company for years and possibly decades to come.

Iovance may be under a different name (acquired by BP) in the not too distant future, but TIL therapy is here to stay.

Good luck to the longs.

And wishes for good health to all that have to get treatment for cancer.

Iovance Biotherapeutics (IOVA) Forecasts Strong Growth Due to Flagship Treatment
Casey Dylan, CIMA
Jan 28, 2025, 02:24 AM

Tipranks: https://www.tipranks.com/news/iovance-biotherapeutics-iova-forecasts-strong-growth-due-to-flagship-treatment

The two largest failures have been inopportune raises and lack of preparedness for the launch and demand.

Thank you for this. This is something that no matter how much you research a company this will not come up.

I hope this makes you a ton of $$!! I'll cheer with you as a build a position

Iovance is significantly undervalued at this time for any number of reasons that have been discussed to death on this board and on numerous other boards. Do your due diligence. Your multiples are not correct, they should be much higher by simple comparisons to similar companies.

Here's just one of any number of discussions regarding valuations. https://finerva.com/report/biotech-genomics-2024-valuation-multiples/ Here's an excerpt:

"Revenue multiples for BioTech & Genomics companies grew throughout all of 2020, peaking at 17.5x in Q4 2021. After a continued fall throughout all of 2021, revenue multiples stabilised between the 5.5x and 7x mark for the past two years. In Q4 2023 the median EV/Revenue Multiple for BioTech & Genomics companies was 5.7x, after hitting a 5x low in Q3."

The point is that Iovance's TAM is significant, the company continues to build out manufacturing to meet the increasing demand, but Iovance is also notorious for limiting their PRs and updates, which makes it hard for an investor to get a handle on how the company is doing. The next few months should prove very telling with all the expected news that's right in front of us including the Q4 report, annual report, and a 2025 forward guidance update is also expected.

If you dig deep, you'll find plenty to support a much higher share price, but right now biotechs have been beaten down, and some like Iovance have been beaten down even more than the average. When the reversal happens, those are the companies that will likely have the bigger bounce.

Lots of investors want to be spoon fed reasons to buy - Iovance just doesn't do that. That's also why so many investors just follow the crowd and wonder why they never quite get those great returns.

It's your money, it's your rules, do your due diligence, make your choices.

Iovance Biotherapeutics (IOVA) Among Billionaire Joseph Edelman’s Long-Term Stock Picks

https://finance.yahoo.com/news/iovance-biotherapeutics-iova-among-billionaire-201009995.html

I’ll start by telling you I’m heavily long here, this is the vast majority of my portfolio. My outlook is several years from now.

Read the last few ERs and their updated corporate deck for most of the answers to your questions.

Management performance over the last year has been ok. The two largest failures have been inopportune raises and lack of preparedness for the launch and demand.

Fundamentally thankfully nothing has changed. Profitability expected in 2026. Frontline melanoma (combo) and secondline NSCLC (mono) approvals likely in 2027. Phase 1/2 for IOV-5001 starting this year.

Do you think IOVA market cap is too high at the moment?

I have a small position just so it's in my portfolio and I can pay attention to it. I noticed bio's have been trading more towards fair market value of about 2-3x revenue. So if it drops to about $1.2B or below, that would be time to start adding. I haven't started DD. But I want to see their debt, cash on hand, quarterly $ burn rate, and most importantly is their management good.

All of this is tremendously exciting. Strong workforce capable of meeting demand. Strong demand which is growing due to recent updates in the NCCN cutaneous melanoma guidelines. Price increase to IL-2 + TILs. And insurance a non-issue.

This is on track towards profitability.

I’m confident the lung data will be good as well. ORR and mDOR already sufficient based on early data. The inclusion parameters forced 2L and not later line as well so that’s going to dramatically help. This wasn’t the case with the melanoma COM-202 trial. Duration is what’s going to really matter. Don’t need it, even >6 will work, but hoping to see 12 months!

A few bonus links for today:

GU Hospital rolls out TIL: https://thehoya.com/news/gu-hospital-rolls-out-breakthrough-melanoma-treatment/

Chris White: https://www.linkedin.com/posts/yourtilspeaker_atw25-mucosalmelanomasurvivor-yourtilspeaker-activity-7285524574358646784-vpQ6?utm_source=share&utm_medium=member_ios

Game changer: https://stocktwits.com/Bamin/message/600367871

Good news regarding Iovance is nearly a daily occurrence. All you have to do is look. The share price will correct in time, but the company is moving forward to bigger and better.

You seem to know enough. Your approach to trading seems in tune. No secret, I'm a fundamental investor and not overly concerned with daily movements. In the long run, I anticipate my return on IOVA will outstrip most IOVA day traders certainly, and likely even some momentum traders and swing traders. Tough to beat the algos on short term action. Bios have been brutalized. If and when we see a reversal, I assume there'll be a rush to get back in. Just a thought and time will tell.

Good luck to the longs.

Interesting today. It feels as if all the dip buyers are no where to be found as they are wary. It has gone down 9 straight days. I find it very perplexing how an analyst just met with management at conference and reiterated $22 price target. I think that the powers that be have shaken out many of the retail shares. I have started a small position and may add if it finds support. The Biotech world has been upside down for a good while. I remember when a company got FDA approval and the stock moved up. In today’s world FDA approval just means that the short interest will increase and the price will be driven down. It’s a short the launch world. I was happy to see that Hindenburg research closed. I was not of the mindset that they were out to help the world by disclosing fraud. They were in it to open a short position and put out a hit piece in order to capitalize on the fear. Did they expose some wrong doings? Yes. But they also were wrong and exaggerated small findings into big deals in order to drive the fear. I think that they got out because there is going to be more scrutiny on short selling with the change in administration. I could be wrong but that is my guess. I hope that the scrutiny happens as it feels to me that IOVA is a victim of HF manipulation. But what do I know.

Sup guys. Just started looking at this one. Broke some key support areas. 3 month down trend. Looks like revenue projected to start ramping up. OS at 304M. How's their debt?

Lol wow, I knew this was going to get ugly..

Another patent granted to Iovance on 1/14/2025: https://patents.justia.com/assignee/iovance-biotherapeutics-inc

Here's the detail: https://patents.justia.com/patent/12194061

OOPS. Did not hit the sell yesterday! An omen?

Analysts still seem to have a lot of question marks on the guidance. Gross Margins should continue to expand, rapidly at first but decreasing over time. They added 100 employees last quarter, assuming most were for manufacturing, salary of $80k+30% fully loaded costs, and 1 slot / employee / qtr would represent less than 5% of COGS, the rest is a spread of fixed which should diminish quickly with growth. Assumed growth rate for 2025 is 25% QoQ which is really high, but given demand ramp, improving drop rates and 56 to 70 ATC growth, should be an achievable stretch (IMO). That level of growth / margin improvement should get to cash breakeven by Q3/Q4 based on my modeling. Will see, but I view that as the inflection point... and we get 2 data read outs and EMA decision as catalysts on top of quarterly earnings. We will see how the data emerges.

Goldman Sachs reiterates Buy with a $22 price target.

https://www.investing.com/news/analyst-ratings/goldman-sachs-reiterates-buy-on-iovance-stock-following-meeting-with-management-93CH-3811217

Goldman Sachs reiterates Buy on Iovance stock following meeting with management
Investing.com
Editor Rachael Rajan
Analyst Ratings
Published 01/14/2025, 06:11 AM
Goldman Sachs reiterates Buy on Iovance stock following meeting with management

IOVA

On Tuesday, Goldman Sachs reaffirmed their Buy rating on Iovance Biotherapeutics (NASDAQ:IOVA) with a steadfast $22.00 price target. The endorsement follows a recent meeting with Iovance's management at an investor conference. The focal point of the discussion was the 2025 outlook for Amtagvi, as it enters its inaugural full calendar year of sales for melanoma treatment.

Iovance has upheld its revenue guidance for fiscal year 2024, projecting $160-165 million, aligning with Goldman Sachs' estimate of $162 million. This guidance reflects a successful Amtagvi launch, indicated by consistent patient demand, enhanced ATC operations, and improved out-of-spec rates.

Despite this positive outlook, Goldman Sachs anticipates ongoing investor discussions, particularly regarding the breakdown of Amtagvi versus Proleukin revenues leading up to the fourth-quarter earnings report. Investors are keen to dissect the fundamentals of the launch and judge the feasibility of the fiscal year 2025 revenue guidance, which stands at $450-475 million as previously announced.

Additionally, gross margins are under scrutiny as investors seek to understand the long-term profitability of the launch. While Amtagvi remains at the forefront of Iovance's 2025 strategy, Goldman Sachs is also closely watching for pipeline updates that could bolster the credibility of Iovance's TIL platform. Notable developments include expected registrational data from the IOV-LUN-202 study in second-line non-small cell lung cancer (NSCLC) and from the Phase 2 IOV-END-201 study in second-line endometrial cancer, both anticipated in 2025.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

I envy your position here. Certainly excited to be able to invest much more heavily once I get a real job and wrap up this Postdoc haha.

But I too am unfazed 🫡

Well said GMH I had similar takeaways.

I got out today. Something stinks here. Got back in when it hit $7.44 a few months ago and grabbed a few moire but not playing here. Will wit and see if the $3.00 train comes in. So sad.

Holy cow. Something is not right here. Down 25% in 6 trading days.

Here is my take on the Corporate Deck Update:

Negatives:
1) Re-iterating guidance was insufficient for The Street. At Q2, they guided (mid-points) of $54M and $162.5. Given the YTD revenue, the Q4 discrete revenue would be $76.7M, but given that $58.6M was a $4.6M beat, re-iterating guidance means new discrete Q4 is $72.1M which is viewed as a significant deceleration.
2) 70 ATCs "including ATCs in final stages of readiness" is a miss. They should have never guided to the higher number as there was no upside. I am still surprised they got this close given 56 ATCs at Q3 earnings call.

Positives:
1) I think the revenue guide as a simple carry-forward rather than a true update, so I think they meet discrete Q4 revenue and come in somewhere in the $165-170M range (with a relief rally from wherever the SP is).
2) Employee count (going back across various updates);
- 2023 JPM (500+)
- Pre-approval Q4 2023 (500+)
- June 3-Q1 2024 (600+)
- Aug 9-Q2 2024 (700+)
- Nov 7-Q3 2024 (750+)
- Jan 13-JPM Update (800+)
Given Fred's Q3 comments that growth was primarily driven by capacity and capacity is limited by staffing (footnote Corp Deck), the trend seems favorable.
3) GM-201 (PD1 knockout) trial P1 is fully enrolled- reported in Nov but just noticed now. These generally take time as patients are usually done sequentially. P2 should enroll quicker as they can be treated in parallel.

Uncertain:
1) Manufacturing Milestone - Fulfill patient demand for commercial launch and clinical trials. Does this mean demand is slowing or are they are now ahead of the curve on hiring? Thinking the latter, but could be some of the former as well.

These are the facts I gleaned from the update and my take on them. Do with them what you will. I always appreciate people sharing facts and their opinion (bull or bear). I personally try to base my investing thesis on facts rather than opinion and think I can discern between the two so appreciate everyone's input.

Yikes, more liquidations..

Sorry to get you riled up. Long term it should find its ground and move up. Your focus on the long term is appreciated. No need to belabor this. Short term it’s headed lower. We all know the important milestones, potential risks and reward which lie ahead Peace.

New corporate deck: https://ir.iovance.com/static-files/f81194ff-6f65-4ed4-af92-67362eb17901

Sunman, if you're the brilliant investor that you continually suggest you are, then why did you invest in the first place and why did you apparently wait so long to sell? I continue to see what the future holds for this company, I accept the risk. You obviously didn't and you want to blame me and others for your supposed failures and losses. If that gets you through the day, so be it.

IOVA is solidly and unfortunately trading with the sector funds right now which has not been good for share price as of late. I know that, most investors here know that, and our hopes of a better share price sooner than later did not materialize. The company still exists, they're still growing revenues, and they're still expanding business operations into numerous new markets. They even issued an updated corporate deck today: https://ir.iovance.com/static-files/f81194ff-6f65-4ed4-af92-67362eb17901

If you're done with IOVA, then be done and move along.

I'll still be here one year from now - assuming Iovance hasn't been acquired by then.

Iovance will still be improving cancer patients' lives and many will even be fully cured. The revenues will continue to rise, macros will likely improve for the sector, and Iovance will also gain more attention from additional investors.

You have no knowledge of who I am and you continually display your foolishness by what you've implied as of late.

Take a vote. If the board wants me gone, I'll be gone. But I'm not going to be silent just because you see the world differently than I do. You can always ignore my comments. I don't recall asking for your approval.

BK

That was a big rant with very little substance to offer other than your recurrent biased viewpoint. Too many what ifs. Highly risky stock. Any setbacks with the trials, failure to meet expectations with revenue and spending and/or sneaky ATM cash raise will be devastating. Near term it’s headed lower. Longer term it may head higher if it mitigates many risk points. Reduce risk seems like a wise option at this time.

Sunman, let me continue on this vein. What is Iovance worth today should BP wish to acquire it? What is its terminal value? What will IOVA be trading at 1 year from now assuming they continue to meet or even slightly beat their guidance numbers. What is Iovance worth to BP if and when nsclc TIL is approved? What will IOVA be trading at after European approval is announced? How about one year after European approval is announced, along with Australia, Canada, and other foreign markets?

I'm not telling anyone when to buy a stock, I'm pointing out what I believe will be a significant winner in the coming years regardless the current share price. At $10, it's cheap. At $6, it's crazy cheap. At $3, the entire market is broken and it becomes a wild west for traders.

You and I both know full well that IOVA is getting killed by algos and the biotech sector being out of favor. It's not the result of some secret conspiracy being waged against Iovance alone. And it's certainly not because Iovance isn't succeeding. They are. Without relevant news, IOVA will continue to languish until order is restored to biotechs or some newsworthy information is released about Iovance specifically. Even assuming a mediocre return to average valuations in biotech, and with the conservative expectations offered in Iovance guidance for 2025, what will IOVA be trading at going into next year? Higher or lower? Answer honestly. Everyone here knows my answer.

You're not happy with your investing at this time? Who is? Will you be happy with your decisions one year from now? I fully believe I will be.

I get it, you're trading a stock, you want to maximize your investment dollars. But what if you're just a casual investor looking for a place to invest a few dollars and you're looking for a good growth company with a promising future? Is IOVA a good purchase right now? Does it fit that category? If I buy IOVA and put it in my IRA, will it look good 2 years from now? 10 years from now? 20 years? Neither one of us knows for sure, but I see what Iovance is doing and I believe they are a company to be reckoned with and they're going to be instrumental in improving cancer care significantly. Does that mean their stock value will go up? Yeah, probably. Tell me one place that you can invest your money where you can't lose? Spoiler alert, there is no such place.

This is not just a board for day traders, nor is it a board that necessarily needs to be reminded that things are tough in biotechs without a corresponding discussion about future value and potential. I have confidence that many investors and day traders can and hopefully do think for themselves. I also wish to share information that benefits the decisions that other investors may make regarding Iovance.

***And even more importantly, I want everyone to think of Iovance when their friends, their loved ones, or even they get that cancer diagnosis and they want to know all of their options. The word is just barely getting around now and we have a long way to go for everyone to have access to this treatment in the event that it's the best option for their specific type of cancer.

I believe Iovance will be a significant company in cancer treatment options. I have no qualms about buying IOVA at any of the prices we've seen over the past year as I expect that IOVA will be significantly higher in the coming years.

I want Iovance to succeed for all kinds of reasons, including my own selfish reason for profit on my investment.

BK

Sunman, that's where you and I must differ - I don't love anything that can't love me back. My primary advice to everyone here is to always do their own due diligence. This is a public forum and a message board. It's a great place to start and to share, but it's not the final step in making investment decisions.

So where is the wind taking us and when will its direction change? I never promised a smooth ride - its biotechs, there's no such thing as easy.

No disrespect but please stop being in love with this stock. Your viewpoint is unwittingly biased. Knowing the direction of the wind is key. I will buy it under $5 and add more closet to $.3, That’s where it is more likely headed. for now. Total capitulation of cash hungry and unprofitable biotechs is on the cards. . God may not be able to save you if they announce any bad news or setbacks during this time. The ones who will survive this assault will
rise again. I hope IOVA is one of them. If and when it does I’ll be owning it too just a lot more than before. Cashed out big time and ready for more devastation ahead.

Pay close attention to the newly awarded patents for Iovance:

https://patents.justia.com/assignee/iovance-biotherapeutics-inc

FWIW, to all of you who don't like the optimism of others, so be it. I'm on the other side of the track, I'm growing tired of all the pessimism around the biotech sector and all the complaints by day traders who don't accept the risk of what they're doing with their money.

The biotech sector is a minefield right now, and many have finally surrendered and limped away as evidenced in the price action. I'll continue to selectively buy shares in companies that I see as ultimate winners.

I guarantee I will not time the market very well and my purchases would sicken all those day traders that expect daily gains and nothing but wins. I will not look like the sharpest tool in the trading shed, but one year, two years, even three years and beyond, I expect to still be excited about my stock purchases and my eventual gains.

At any time, the market could fall in love with a stock like IOVA, I prefer to own it when it does.

Good luck to my fellow investors.

Hicham, I'm still on this ride with you.

To all, looking at outside evidence of where IOVA is relative to XBI and LABU, I challenge you all to go look at the 5 year comparison, the 1 year comparison, and even the 3 month and 1 month. What you'll find is that the game keeps taking IOVA back to the median with a tendency more toward a tie with LABU. This is why trading a stock like IOVA is so challenging (as is all trading for that matter and why most day traders lose money), you're trying to compete against computer trading and all those algos. I'm an investor who tries to focus on fundaments, but I accept that there's a lot of outside pressures that have nothing to do with the company per se.

Yes, current share price stinks, but Iovance is still building a fantastic business and delivering a winning new cancer treatment based on the testimony of thousands of people in the oncology sector. The share price doesn't reflect it yet, but it will. I can be excited about what Iovance has to offer and accept at the same time that the market value doesn't necessarily jibe with what we see as future value. In time, it will, but knowing the when is far more challenging than knowing if.

I'm ultimately responsible for my own trading decisions as are each of you. I see what's coming for Iovance. I don't know for certain when the market value will be more reflective of IOVA's fair value based on what we expect for future revenues, but I'm confident it will.

The biotech sector has been a bear and despite all that we expect for this company, IOVA still trades with the sector as well and as such has fallen out of favor. I expect the company to be wildly successful, but the market hasn't gotten to that point yet. In time, it will. If the ride is too rough, you all have control over your own investments. Your money, your rules. Buy, hold, or sell, it's your decision on what to do with your money. You can base your decision on what others may say, but that is still your decision. My money, my rules, and my decision was to buy more and hold.

Some see me as a cheerleader - I am and I'm excited for TIL therapy to continue in it's market penetration. It is one big step forward for improving cancer treatment. Iovance has many more big steps coming. The company's success will prove to be a reward to shareholders and even more importantly a potential improvement or cure for 10's of thousands of cancer patients that were running out of options.

Good luck to the longs.

Total nonsense. I may liquidate my holdings and wait!